Physiologic Insulin Resensitization

Deep Dive: Effects of Diabetes & Chronic Kidney Disease (CKD)

Diabetes and CKD create a compounding cycle of systemic damage that affects nearly every organ system in the body. When insulin resistance or insufficient insulin production persists, glucose remains elevated in the bloodstream, leading to progressive cellular toxicity, vascular injury, and inflammatory stress.

Impact of Type 1 & Type 2 Diabetes

In both Type 1 and Type 2 Diabetes, impaired glucose regulation results in:

• Neuropathy: Damage to peripheral nerves causing numbness, burning, tingling, and chronic pain.
• Microvascular Damage: Reduced blood flow affecting the eyes (retinopathy), kidneys (nephropathy), and extremities.
• Chronic Inflammation: Increased oxidative stress that accelerates tissue degeneration.
• Mitochondrial Dysfunction: Impaired energy production causing fatigue and poor cellular repair.
• Cardiometabolic Strain: Increased risk of heart attack, stroke, and metabolic collapse.

Impact of Chronic Kidney Disease (Stages 1–5)

CKD progresses from mild loss of kidney function to complete renal failure. As kidney filtration declines:

• Stage 1–2: Early damage with subtle symptoms such as fatigue and fluid imbalance.
• Stage 3: Reduced GFR, increased toxin buildup, hypertension, and early anemia.
• Stage 4: Severe filtration decline, swelling, electrolyte imbalances, and cardiovascular stress.
• Stage 5 (End-Stage Renal Disease): Dialysis or transplant required to sustain life.

PIR Therapy (Physiologic Insulin Resensitization) works by restoring the natural rhythmic insulin signaling process, enhancing cellular uptake, improving mitochondrial activity, and reducing insulin resistance at the root level. This mechanism supports stabilization and potential reversal of damage while improving systemic efficiency.